Haemonetics announced that CSL Plasma plans to deploy its NexSys PCS devices with Persona PLUS technology across all its U.S. plasma collection centers by the end of 2027. This significant expansion of their supply relationship is a major positive for Haemonetics, driving its stock to a 52-week high, despite the company maintaining its fiscal 2027 guidance due to implementation uncertainties.
Haemonetics disclosed that CSL Plasma, a major customer, intends to fully integrate Haemonetics' NexSys PCS devices and related disposables across all its U.S. plasma collection centers by 2027. This represents a substantial expansion of their existing supply agreement, indicating strong demand and confidence in Haemonetics' technology. The news is a significant positive catalyst for Haemonetics, as evidenced by its stock hitting a 52-week high. While the company maintained its fiscal 2027 guidance due to ongoing finalization of deployment details and potential changes in the rollout schedule, the long-term implications point to increased recurring revenue from disposable products. Traders should note the potential for upside revisions to future guidance once more details are solidified, but also acknowledge the risk of delays or changes in CSL Plasma's purchasing volumes.